A two-for-one approach to boost melanoma immunotherapy

Researchers uncover potential biomarkers of positive response to immunotherapy

Study hints at how cancer immunotherapy can be safer

Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer